225 related articles for article (PubMed ID: 26930419)
1. Rosuvastatin: Beyond the cholesterol-lowering effect.
Cortese F; Gesualdo M; Cortese A; Carbonara S; Devito F; Zito A; Ricci G; Scicchitano P; Ciccone MM
Pharmacol Res; 2016 May; 107():1-18. PubMed ID: 26930419
[TBL] [Abstract][Full Text] [Related]
2. Statin-mediated inhibition of cholesterol synthesis induces cytoprotective autophagy in human leukemic cells.
Vilimanovich U; Bosnjak M; Bogdanovic A; Markovic I; Isakovic A; Kravic-Stevovic T; Mircic A; Trajkovic V; Bumbasirevic V
Eur J Pharmacol; 2015 Oct; 765():415-28. PubMed ID: 26358205
[TBL] [Abstract][Full Text] [Related]
3. The effects of rosuvastatin on lipid-lowering, inflammatory, antioxidant and fibrinolytics blood biomarkers are influenced by Val16Ala superoxide dismutase manganese-dependent gene polymorphism.
Duarte T; da Cruz IB; Barbisan F; Capelleto D; Moresco RN; Duarte MM
Pharmacogenomics J; 2016 Nov; 16(6):501-506. PubMed ID: 26882122
[TBL] [Abstract][Full Text] [Related]
4. Statins: pros and cons.
Pinal-Fernandez I; Casal-Dominguez M; Mammen AL
Med Clin (Barc); 2018 May; 150(10):398-402. PubMed ID: 29292104
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
Pedersen TR
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
[TBL] [Abstract][Full Text] [Related]
6. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
Landsberger M; Jantzen F; Könemann S; Felix SB
Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
[TBL] [Abstract][Full Text] [Related]
7. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
Stalker TJ; Lefer AM; Scalia R
Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats.
Okada Y; Yamaguchi K; Nakajima T; Nishikawa T; Jo M; Mitsumoto Y; Kimura H; Nishimura T; Tochiki N; Yasui K; Mitsuyoshi H; Minami M; Kagawa K; Okanoue T; Itoh Y
Liver Int; 2013 Feb; 33(2):301-11. PubMed ID: 23295058
[TBL] [Abstract][Full Text] [Related]
9. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
März W; Köenig W
J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
[TBL] [Abstract][Full Text] [Related]
10. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
11. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
12. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of simvastatin and rosuvastatin on trinitrobenzene sulfonic acid-induced colitis in rats.
Maheshwari RA; Balaraman R; Sailor GU; Sen DB
Indian J Pharmacol; 2015; 47(1):17-21. PubMed ID: 25821305
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin: Role in Secondary Prevention of Cardiovascular Disease.
Wander GS; Hukkeri MYK; Yalagudri S; Mahajan B; Panda AT
J Assoc Physicians India; 2018 Mar; 66(3):70-4. PubMed ID: 30341873
[TBL] [Abstract][Full Text] [Related]
15. Statins and their role in vascular protection.
Mason JC
Clin Sci (Lond); 2003 Sep; 105(3):251-66. PubMed ID: 12793855
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.
Barrios V; Escobar C
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1317-27. PubMed ID: 19900015
[TBL] [Abstract][Full Text] [Related]
17. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk.
Vavlukis A; Vavlukis M; Dimovski A; Petrushevska G; Eftimov A; Domazetovska S; Mladenovska K
Acta Pharm; 2022 Jun; 72(2):303-315. PubMed ID: 36651514
[TBL] [Abstract][Full Text] [Related]
19. An update on the benefits and risks of rosuvastatin therapy.
Toth PP
Postgrad Med; 2014 Mar; 126(2):7-17. PubMed ID: 24685964
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents.
Capra V; Rovati GE
Pulm Pharmacol Ther; 2014 Feb; 27(1):10-6. PubMed ID: 23806820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
